NASDAQ:ZFGNZafgen Stock Price, Forecast & News

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZFGN shares have increased by 1,782.1% and is now trading at $16.00. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen.

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zafgen.

Zafgen Inc (NASDAQ:ZFGN) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. View Zafgen's earnings history.

3 Wall Street analysts have issued 12-month target prices for Zafgen's shares. Their forecasts range from $0.78 to $0.78. On average, they expect Zafgen's stock price to reach $0.78 in the next twelve months. This suggests that the stock has a possible downside of 95.1%. View analysts' price targets for Zafgen.

Media headlines about ZFGN stock have trended extremely positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zafgen earned a media sentiment score of 5.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutZafgen.

Zafgen saw a decline in short interest in May. As of May 15th, there was short interest totaling 523,100 shares, a decline of 9.4% from the April 30th total of 577,100 shares. Based on an average daily volume of 182,000 shares, the short-interest ratio is currently 2.9 days. Approximately 1.8% of the shares of the company are sold short. View Zafgen's Current Options Chain.

Some companies that are related to Zafgen include Apellis Pharmaceuticals (APLS), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX), Pacira Biosciences (PCRX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Ligand Pharmaceuticals (LGND), SAGE Therapeutics (SAGE), Passage Bio (ZNTL), Zymeworks (ZYME), Xencor (XNCR), Epizyme (EPZM) and Aurinia Pharmaceuticals (AUPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), SCYNEXIS (SCYX), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Esperion Therapeutics (ESPR) and Gilead Sciences (GILD).

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Zafgen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Sphera Funds Management LTD. (8.44%), Soleus Capital Management L.P. (3.60%), Orbimed Advisors LLC (2.95%), Russell Investments Group Ltd. (0.70%), Two Sigma Investments LP (0.60%) and Two Sigma Advisers LP (0.57%). View institutional ownership trends for Zafgen.

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Russell Investments Group Ltd., Hikari Power Ltd, and Two Sigma Advisers LP. View insider buying and selling activity for Zafgen.

ZFGN stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Soleus Capital Management L.P., and Orbimed Advisors LLC. View insider buying and selling activity for Zafgen.

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZFGN stock can currently be purchased for approximately $16.00.

Zafgen has a market capitalization of $599.52 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

The official website for Zafgen is www.zafgen.com.

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]